Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence G Lum

Showing results (21-30 of 90) with videos related to

Pageof 9
Sort By:
Pediatric Clinics of North America|December 2, 2014
Hematopoietic cell transplantation and cellular therapeutics in the treatment of childhood malignanciesKanwaldeep Mallhi, Lawrence G Lum, Kirk R Schultz, et al.
Cancer Immunology, Immunotherapy : CII|July 4, 2012
Generation and immunologic functions of Th17 cells in malignant gliomasManjeera Paladugu, Archana Thakur, Lawrence G Lum, et al.
Prostate Cancer|March 25, 2015
Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer PatientsUlka Vaishampayan, Archana Thakur, Ritesh Rathore, et al.
Journal of Cellular Biochemistry|June 18, 2005
Virtual reality of stem cell transplantation to repair injured myocardiumLawrence G Lum, James F Padbury, Pamela A Davol, et al.
Journal of Hematology & Oncology|December 10, 2021
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicityZhaoming Wang, Chaobo Yin, Lawrence G Lum, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
LAG3+ CD8+ T cell Subset Drives HR+/HER2- Breast Cancer Reduction in Bispecific Antibody Armed Activated T Cell TherapyRobert Weldon Barnes, Archana Thakur, Suna Onengut-Gumuscu, et al.
Journal of Cancer Research and Clinical Oncology|May 26, 2020
Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept studyArchana Thakur, John Scholler, Dana L Schalk, et al.
Frontiers in Oncology|May 21, 2020
Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1<sup>+</sup> Myeloma Cells and Release Type-1 CytokinesLawrence G Lum, Archana Thakur, Abdalla Elhakiem, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 12, 2025
LAG3+ CD8+ T cell subset drives HR+/HER2- breast cancer reduction in bispecific antibody armed activated T cell therapyRobert Weldon Barnes, Archana Thakur, Suna Onengut-Gumuscu, et al.
Transfusion|July 13, 2011
Activated T cells from umbilical cord blood armed with anti-CD3 × anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplantsArchana Thakur, Carly Sorenson, Oxana Norkina, et al.
Pageof 9

Showing results (21-30 of 90) with videos related to

Sort By:
Pageof 9
Pediatric Clinics of North America|December 2, 2014
Hematopoietic cell transplantation and cellular therapeutics in the treatment of childhood malignanciesKanwaldeep Mallhi, Lawrence G Lum, Kirk R Schultz, et al.
Cancer Immunology, Immunotherapy : CII|July 4, 2012
Generation and immunologic functions of Th17 cells in malignant gliomasManjeera Paladugu, Archana Thakur, Lawrence G Lum, et al.
Prostate Cancer|March 25, 2015
Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer PatientsUlka Vaishampayan, Archana Thakur, Ritesh Rathore, et al.
Journal of Cellular Biochemistry|June 18, 2005
Virtual reality of stem cell transplantation to repair injured myocardiumLawrence G Lum, James F Padbury, Pamela A Davol, et al.
Journal of Hematology & Oncology|December 10, 2021
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicityZhaoming Wang, Chaobo Yin, Lawrence G Lum, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
LAG3+ CD8+ T cell Subset Drives HR+/HER2- Breast Cancer Reduction in Bispecific Antibody Armed Activated T Cell TherapyRobert Weldon Barnes, Archana Thakur, Suna Onengut-Gumuscu, et al.
Journal of Cancer Research and Clinical Oncology|May 26, 2020
Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept studyArchana Thakur, John Scholler, Dana L Schalk, et al.
Frontiers in Oncology|May 21, 2020
Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1<sup>+</sup> Myeloma Cells and Release Type-1 CytokinesLawrence G Lum, Archana Thakur, Abdalla Elhakiem, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 12, 2025
LAG3+ CD8+ T cell subset drives HR+/HER2- breast cancer reduction in bispecific antibody armed activated T cell therapyRobert Weldon Barnes, Archana Thakur, Suna Onengut-Gumuscu, et al.
Transfusion|July 13, 2011
Activated T cells from umbilical cord blood armed with anti-CD3 × anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplantsArchana Thakur, Carly Sorenson, Oxana Norkina, et al.
Pageof 9